-
1
-
-
84857017872
-
Epidemiology of invasive cutaneous melanoma
-
RM MacKie A Hauschild AM Eggermont 2009 Epidemiology of invasive cutaneous melanoma Ann Oncol 20 Suppl 6 1 7
-
(2009)
Ann Oncol
, vol.20
, Issue.SUPPL. 6
, pp. 1-7
-
-
MacKie, R.M.1
Hauschild, A.2
Eggermont, A.M.3
-
2
-
-
0036788419
-
Radiation therapy of malignant melanoma
-
12380058 10.1016/S0733-8635(02)00029-3
-
JS Cooper 2002 Radiation therapy of malignant melanoma Dermatol Clin 20 713 716 12380058 10.1016/S0733-8635(02)00029-3
-
(2002)
Dermatol Clin
, vol.20
, pp. 713-716
-
-
Cooper, J.S.1
-
4
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
20818844 10.1056/NEJMoa1002011 1:CAS:528:DC%2BC3cXhtVyksb3M
-
KT Flaherty I Puzanov KB Kim, et al. 2010 Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 809 819 20818844 10.1056/NEJMoa1002011 1:CAS:528:DC%2BC3cXhtVyksb3M
-
(2010)
N Engl J Med
, vol.363
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
-
5
-
-
78249254899
-
BRAF, a target in melanoma: Implications for solid tumor drug development
-
20629085 10.1002/cncr.25261 1:CAS:528:DC%2BC3cXhsVymtL7L
-
KT Flaherty G McArthur 2010 BRAF, a target in melanoma: implications for solid tumor drug development Cancer 116 4902 4913 20629085 10.1002/cncr.25261 1:CAS:528:DC%2BC3cXhsVymtL7L
-
(2010)
Cancer
, vol.116
, pp. 4902-4913
-
-
Flaherty, K.T.1
McArthur, G.2
-
6
-
-
77950672269
-
Targeting multiple kinase pathways: A change in paradigm
-
20215532 10.1158/1078-0432.CCR-09-3182 1:CAS:528:DC%2BC3cXktFygu7w%3D
-
L Gossage T Eisen 2010 Targeting multiple kinase pathways: a change in paradigm Clin Cancer Res 16 1973 1978 20215532 10.1158/1078-0432.CCR-09-3182 1:CAS:528:DC%2BC3cXktFygu7w%3D
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1973-1978
-
-
Gossage, L.1
Eisen, T.2
-
7
-
-
59649123810
-
Integrating BRAF/MEK inhibitors into combination therapy for melanoma
-
19156138 10.1038/sj.bjc.6604891 1:CAS:528:DC%2BD1MXhsFektr4%3D
-
KS Smalley KT Flaherty 2009 Integrating BRAF/MEK inhibitors into combination therapy for melanoma Br J Cancer 100 431 435 19156138 10.1038/sj.bjc.6604891 1:CAS:528:DC%2BD1MXhsFektr4%3D
-
(2009)
Br J Cancer
, vol.100
, pp. 431-435
-
-
Smalley, K.S.1
Flaherty, K.T.2
-
8
-
-
49649118852
-
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
-
18559533 10.1158/0008-5472.CAN-07-6787 1:CAS:528:DC%2BD1cXnt1ejsbs%3D
-
C Montagut SV Sharma T Shioda, et al. 2008 Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res 68 4853 4861 18559533 10.1158/0008-5472.CAN-07-6787 1:CAS:528:DC%2BD1cXnt1ejsbs%3D
-
(2008)
Cancer Res
, vol.68
, pp. 4853-4861
-
-
Montagut, C.1
Sharma, S.V.2
Shioda, T.3
-
9
-
-
69949151386
-
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
-
19629074 10.1038/nrd2871 1:CAS:528:DC%2BD1MXovFylur4%3D
-
PA Janne N Gray J Settleman 2009 Factors underlying sensitivity of cancers to small-molecule kinase inhibitors Nat Rev Drug Discov 8 709 723 19629074 10.1038/nrd2871 1:CAS:528:DC%2BD1MXovFylur4%3D
-
(2009)
Nat Rev Drug Discov
, vol.8
, pp. 709-723
-
-
Janne, P.A.1
Gray, N.2
Settleman, J.3
-
10
-
-
77949732073
-
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
-
20179705 10.1038/nature08902 1:CAS:528:DC%2BC3cXjsFWjsrs%3D
-
PI Poulikakos C Zhang G Bollag KM Shokat N Rosen 2010 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 427 430 20179705 10.1038/nature08902 1:CAS:528:DC%2BC3cXjsFWjsrs%3D
-
(2010)
Nature
, vol.464
, pp. 427-430
-
-
Poulikakos, P.I.1
Zhang, C.2
Bollag, G.3
Shokat, K.M.4
Rosen, N.5
-
11
-
-
78650303507
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
-
21107323 10.1038/nature09626 1:CAS:528:DC%2BC3cXhsVOrsbjI
-
R Nazarian H Shi Q Wang, et al. 2010 Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 973 977 21107323 10.1038/nature09626 1:CAS:528:DC%2BC3cXhsVOrsbjI
-
(2010)
Nature
, vol.468
, pp. 973-977
-
-
Nazarian, R.1
Shi, H.2
Wang, Q.3
-
12
-
-
78650309875
-
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
-
21107320 10.1038/nature09627 1:CAS:528:DC%2BC3cXhsVOrsLvP
-
CM Johannessen JS Boehm SY Kim, et al. 2010 COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 968 972 21107320 10.1038/nature09627 1:CAS:528:DC%2BC3cXhsVOrsLvP
-
(2010)
Nature
, vol.468
, pp. 968-972
-
-
Johannessen, C.M.1
Boehm, J.S.2
Kim, S.Y.3
-
13
-
-
74949136580
-
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies
-
20028761 10.1158/1078-0432.CCR-09-2345 1:CAS:528:DC%2BC3cXotFyn
-
M Campoli R Ferris S Ferrone X Wang 2010 Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies Clin Cancer Res 16 11 20 20028761 10.1158/1078-0432.CCR-09-2345 1:CAS:528:DC%2BC3cXotFyn
-
(2010)
Clin Cancer Res
, vol.16
, pp. 11-20
-
-
Campoli, M.1
Ferris, R.2
Ferrone, S.3
Wang, X.4
-
14
-
-
77957829001
-
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer
-
20852124 10.1093/jnci/djq343
-
X Wang T Osada Y Wang, et al. 2010 CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer J Natl Cancer Inst 102 1496 1512 20852124 10.1093/jnci/djq343
-
(2010)
J Natl Cancer Inst
, vol.102
, pp. 1496-1512
-
-
Wang, X.1
Osada, T.2
Wang, Y.3
-
15
-
-
77953496846
-
CSPG4 in cancer: Multiple roles
-
20455858 10.2174/156652410791316977 1:CAS:528:DC%2BC3cXmsVamsbg%3D
-
X Wang Y Wang L Yu, et al. 2010 CSPG4 in cancer: multiple roles Curr Mol Med 10 419 429 20455858 10.2174/156652410791316977 1:CAS:528: DC%2BC3cXmsVamsbg%3D
-
(2010)
Curr Mol Med
, vol.10
, pp. 419-429
-
-
Wang, X.1
Wang, Y.2
Yu, L.3
-
16
-
-
3042594595
-
Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms
-
DOI 10.1083/jcb.200403174
-
J Yang MA Price CL Neudauer, et al. 2004 Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms J Cell Biol 165 881 891 15210734 10.1083/jcb.200403174 1:CAS:528:DC%2BD2cXltFKltbY%3D (Pubitemid 38821978)
-
(2004)
Journal of Cell Biology
, vol.165
, Issue.6
, pp. 881-891
-
-
Yang, J.1
Price, M.A.2
Neudauer, C.L.3
Wilson, C.4
Ferrone, S.5
Xia, H.6
Iida, J.7
Simpson, M.A.8
McCarthy, J.B.9
-
17
-
-
70350227318
-
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition
-
19738072 10.1158/0008-5472.CAN-08-4626 1:CAS:528:DC%2BD1MXht1Skt7rK
-
J Yang MA Price GY Li, et al. 2009 Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to- mesenchymal transition Cancer Res 69 7538 7547 19738072 10.1158/0008-5472.CAN- 08-4626 1:CAS:528:DC%2BD1MXht1Skt7rK
-
(2009)
Cancer Res
, vol.69
, pp. 7538-7547
-
-
Yang, J.1
Price, M.A.2
Li, G.Y.3
-
18
-
-
9444251067
-
Integrin αv-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen
-
DOI 10.1083/jcb.200404018
-
W Bao S Stromblad 2004 Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen J Cell Biol 167 745 756 15557124 10.1083/jcb.200404018 1:CAS:528:DC%2BD2cXhtVaqtb3P (Pubitemid 39565154)
-
(2004)
Journal of Cell Biology
, vol.167
, Issue.4
, pp. 745-756
-
-
Bao, W.1
Stromblad, S.2
-
19
-
-
48249126226
-
BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC
-
Schrama D, Keller G, Houben R, et al. BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC. J Carcinog 2008;7:1.
-
(2008)
J Carcinog
, vol.7
, pp. 1
-
-
Schrama, D.1
Keller, G.2
Houben, R.3
-
20
-
-
77950954465
-
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
-
Sondergaard JN, Nazarian R, Wang Q, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010;8:39.
-
(2010)
J Transl Med
, vol.8
, pp. 39
-
-
Sondergaard, J.N.1
Nazarian, R.2
Wang, Q.3
-
21
-
-
77954376912
-
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
-
20551065 10.1158/0008-5472.CAN-10-0646 1:CAS:528:DC%2BC3cXot1Wks7Y%3D
-
H Yang B Higgins K Kolinsky, et al. 2010 RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res 70 5518 5527 20551065 10.1158/0008-5472.CAN-10-0646 1:CAS:528:DC%2BC3cXot1Wks7Y%3D
-
(2010)
Cancer Res
, vol.70
, pp. 5518-5527
-
-
Yang, H.1
Higgins, B.2
Kolinsky, K.3
-
22
-
-
65249119397
-
Phosphorylated 4E-BP1 is associated with poor survival in melanoma
-
19336517 10.1158/1078-0432.CCR-08-2336
-
KE O'Reilly M Warycha MA Davies, et al. 2009 Phosphorylated 4E-BP1 is associated with poor survival in melanoma Clin Cancer Res 15 2872 2878 19336517 10.1158/1078-0432.CCR-08-2336
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2872-2878
-
-
O'Reilly, K.E.1
Warycha, M.2
Davies, M.A.3
-
23
-
-
66449103375
-
Structure and regulation of the versican promoter: The versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells
-
19269971 10.1074/jbc.M807108200 1:CAS:528:DC%2BD1MXltVClsr4%3D
-
C Domenzain-Reyna D Hernandez L Miquel-Serra, et al. 2009 Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells J Biol Chem 284 12306 12317 19269971 10.1074/jbc.M807108200 1:CAS:528:DC%2BD1MXltVClsr4%3D
-
(2009)
J Biol Chem
, vol.284
, pp. 12306-12317
-
-
Domenzain-Reyna, C.1
Hernandez, D.2
Miquel-Serra, L.3
-
24
-
-
77956513286
-
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
-
20823850 10.1038/nature09454 1:CAS:528:DC%2BC3cXht1ajtbfK
-
G Bollag P Hirth J Tsai, et al. 2010 Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 596 599 20823850 10.1038/nature09454 1:CAS:528:DC%2BC3cXht1ajtbfK
-
(2010)
Nature
, vol.467
, pp. 596-599
-
-
Bollag, G.1
Hirth, P.2
Tsai, J.3
-
25
-
-
11144232998
-
Human high molecular weight-melanoma-associated antigen (HMW-MAA): A melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance
-
DOI 10.1615/CritRevImmunol.v24.i4.40
-
MR Campoli CC Chang T Kageshita X Wang JB McCarthy S Ferrone 2004 Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance Crit Rev Immunol 24 267 296 15588226 10.1615/CritRevImmunol.v24.i4. 40 1:CAS:528:DC%2BD2MXotFOksw%3D%3D (Pubitemid 40052428)
-
(2004)
Critical Reviews in Immunology
, vol.24
, Issue.4
, pp. 267-296
-
-
Campoli, M.R.1
Chang, C.-C.2
Kageshita, T.3
Wang, X.4
McCarthy, J.B.5
Ferrone, S.6
-
26
-
-
0024239488
-
Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA-DR,DP monoclonal antibody CR11-462
-
DOI 10.1016/0198-8859(88)90061-4
-
F Perosa S Ferrone 1988 Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA-DR, DP monoclonal antibody CR11-462 Hum Immunol 23 255 269 3266207 10.1016/0198-8859(88)90061-4 1:STN:280:DyaL1M7nsVSmsQ%3D%3D (Pubitemid 19009573)
-
(1988)
Human Immunology
, vol.23
, Issue.4
, pp. 255-269
-
-
Perosa, F.1
Ferrrone, S.2
-
27
-
-
0024515896
-
Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: Comparison with other methods of purification
-
M Temponi T Kageshita F Perosa R Ono H Okada S Ferrone 1989 Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification Hybridoma 8 85 95 2784406 10.1089/hyb.1989.8.85 1:CAS:528:DyaL1MXhvFSmt7o%3D (Pubitemid 19082761)
-
(1989)
Hybridoma
, vol.8
, Issue.1
, pp. 85-95
-
-
Temponi, M.1
Kageshita, T.2
Perosa, F.3
Ono, K.4
Okada, H.5
Ferrone, S.6
-
28
-
-
0031586337
-
A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen
-
DOI 10.1006/excr.1997.3674
-
MA Burg A Nishiyama WB Stallcup 1997 A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen Exp Cell Res 235 254 264 9281375 10.1006/excr.1997.3674 1:CAS:528:DyaK2sXlvVKgtLs%3D (Pubitemid 27381704)
-
(1997)
Experimental Cell Research
, vol.235
, Issue.1
, pp. 254-264
-
-
Burg, M.A.1
Nishiyama, A.2
Stallcup, W.B.3
-
29
-
-
0031685581
-
Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells
-
DOI 10.1002/(SICI)1097-4652(199 811)177:2<299::AID-JCP12>3.0.CO;2-5
-
MA Burg KA Grako WB Stallcup 1998 Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells J Cell Physiol 177 299 312 9766527 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3. 0.CO;2-5 1:CAS:528:DyaK1cXmsValt70%3D (Pubitemid 28452831)
-
(1998)
Journal of Cellular Physiology
, vol.177
, Issue.2
, pp. 299-312
-
-
Burg, M.A.1
Grako, K.A.2
Stallcup, W.B.3
-
30
-
-
77953276524
-
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
-
20531415 10.1038/sj.bjc.6605714 1:CAS:528:DC%2BC3cXntFSnsrc%3D
-
KH Paraiso IV Fedorenko LP Cantini, et al. 2010 Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy Br J Cancer 102 1724 1730 20531415 10.1038/sj.bjc.6605714 1:CAS:528:DC%2BC3cXntFSnsrc%3D
-
(2010)
Br J Cancer
, vol.102
, pp. 1724-1730
-
-
Paraiso, K.H.1
Fedorenko, I.V.2
Cantini, L.P.3
-
31
-
-
77949354563
-
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells
-
20149136 10.1111/j.1755-148X.2010.00685.x 1:CAS:528:DC%2BC3cXltF2ls7s%3D
-
R Halaban W Zhang A Bacchiocchi, et al. 2010 PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells Pigment Cell Melanoma Res 23 190 200 20149136 10.1111/j.1755-148X.2010.00685.x 1:CAS:528:DC%2BC3cXltF2ls7s%3D
-
(2010)
Pigment Cell Melanoma Res
, vol.23
, pp. 190-200
-
-
Halaban, R.1
Zhang, W.2
Bacchiocchi, A.3
-
32
-
-
78650008177
-
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3 K
-
21156289 10.1016/j.ccr.2010.11.023 1:CAS:528:DC%2BC3cXhsFGhsbjJ
-
J Villanueva A Vultur JT Lee, et al. 2010 Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3 K Cancer Cell 18 683 695 21156289 10.1016/j.ccr.2010.11.023 1:CAS:528:DC%2BC3cXhsFGhsbjJ
-
(2010)
Cancer Cell
, vol.18
, pp. 683-695
-
-
Villanueva, J.1
Vultur, A.2
Lee, J.T.3
-
33
-
-
79961173275
-
-
[cited; Available from:
-
Flaherty K. 2011 [cited; Available from: http://www.dfhcc.harvard.edu/ news/news/article/4126/334/?PHPSESSID=c84186b744715f955d507b9356d0f3b2.
-
(2011)
-
-
Flaherty, K.1
-
34
-
-
0026584248
-
Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma
-
1731316 10.1073/pnas.89.2.466 1:STN:280:DyaK387hsFKrsQ%3D%3D
-
A Mittelman ZJ Chen H Yang GY Wong S Ferrone 1992 Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma Proc Natl Acad Sci USA 89 466 470 1731316 10.1073/pnas.89.2.466 1:STN:280:DyaK387hsFKrsQ%3D%3D
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 466-470
-
-
Mittelman, A.1
Chen, Z.J.2
Yang, H.3
Wong, G.Y.4
Ferrone, S.5
|